Wholesale-Drugs, Proprietaries & Druggists' Sundries stocks

3 distinct companies in our coverage share this SEC industry code, including Cardinal Health, Inc. (CAH), Cencora, Inc. (COR), McKesson Corporation (MCK). Explore what each business does and open its annual filing below.

What this peer group tells you

The SEC classifies these issuers under “Wholesale-Drugs, Proprietaries & Druggists' Sundries” (SIC 5122). A shared code is a starting point for finding comparable businesses. Product mix, geography and customers can still differ substantially. Read the company descriptions before treating the group as direct competitors.

Fiscal calendars in this group

Align the reporting periods before comparing annual results. Companies with different year ends report different 12-month windows.

Fiscal year end (SEC)Companies
March 31MCK
June 30CAH
September 30COR

Wholesale-Drugs, Proprietaries & Druggists' Sundries stocks: company profiles and annual filings

Cencora, Inc. (COR)

Cencora is a pharmaceutical wholesaler distributing drugs and providing specialty and logistics services.

Fiscal year end in SEC snapshot
September 30
Annual report period end
2025-09-30
10-K filed 2025-11-25

Sources and method

Industry codes and annual filing references come from the SEC submissions snapshot linked to each issuer in our company catalog (snapshot ; newer filings may exist). Only groups with at least three distinct issuers, business descriptions and annual filing links are included. Multiple share classes of one issuer count as one company. This is a coverage directory, not a complete industry census or a ranking of investments.

SEC Standard Industrial Classification code list explains the classification system. Read our research methodology or browse all industry directories.

What do the wholesale-drugs, proprietaries & druggists' sundries numbers leave unanswered?

Financials describe the business. The next question is which assumptions an investment thesis depends on. Explore the member reports below for analysis of catalysts, risks, and what would change the view. $39/month or $249/year.

$39/mo or $249/yr · cancel future renewals anytime · sources included